A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Author(s) -
Mark R. Gilbert,
James J. Dignam,
Terri S. Armstrong,
Jeffrey S. Wefel,
Deborah T. Blumenthal,
Michael A. Vogelbaum,
Howard Colman,
Arnab Chakravarti,
Stephanie L. Pugh,
Minhee Won,
Robert Jeraj,
Paul D. Brown,
Kurt A. Jaeckle,
David Schiff,
Volker W. Stieber,
David Brachman,
Maria WernerWasik,
Ivo W. TremontLukats,
Erik P. Sulman,
Kenneth Aldape,
Walter J. Curran,
Minesh P. Mehta
Publication year - 2014
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1308573
Subject(s) - bevacizumab , temozolomide , medicine , glioblastoma , oncology , standard of care , radiation therapy , vascular endothelial growth factor , randomized controlled trial , chemotherapy , vegf receptors , cancer research
Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom